|
US2020390708A1
|
|
Multilayer beads for pharmaceutical use
|
|
US2017020890A1
|
|
Pharmaceutical composition comprising fatty acid derivative
|
|
US2016120840A1
|
|
Method and composition for treating nonerosive reflux disease
|
|
US2015099802A1
|
|
Selective tumor treatment
|
|
US2015057351A1
|
|
Method for treating neuropathic pain
|
|
US2014371304A1
|
|
Method for suppressing tumorigenicity of stem cells
|
|
TW201345524A
|
|
Tricyclo compound-polymer conjugate
|
|
TW201347774A
|
|
Fatty acid derivative-polymer conjugate
|
|
WO2013161973A1
|
|
Method for treating irritable bowel syndrome with diarrhea
|
|
AU2013203903A1
|
|
Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound
|
|
KR20140076551A
|
|
Method for treating schizophrenia
|
|
CA2831869A1
|
|
Method for modulating cytokine activity
|
|
KR20140035363A
|
|
Method for treating asthenopia
|
|
JP2011032262A
|
|
Pharmaceutical composition for long term use of nsaid
|
|
US2011034424A1
|
|
Method for the long term nsaid use
|
|
JP2010070577A
|
|
Pharmaceutical composition for treating ocular hypertension or glaucoma
|
|
US2009012165A1
|
|
Pharmaceutical combination of nsaid and prostaglandin compound
|
|
US2009030072A1
|
|
Pharmaceutical combination of opioid and prostaglandin compound
|
|
EP2114411A2
|
|
Composition and method for protecting mitochondria
|
|
EP2059247A1
|
|
Method and composition for promoting gastrointestinal bicarbonate secretion
|
